These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23684903)

  • 1. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
    Matsuura K; Tanaka Y; Hasegawa I; Ohno T; Tokuda H; Kurbanov F; Sugauchi F; Nojiri S; Joh T; Mizokami M
    J Clin Microbiol; 2009 Feb; 47(2):385-9. PubMed ID: 19091819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.
    Miyagi Y; Nomura H; Yamashita N; Tanimoto H; Ito K; Masaki N; Mizokami M; Shibuya T
    J Infect Chemother; 2013 Feb; 19(1):63-9. PubMed ID: 22821355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.
    Ogawa E; Furusyo N; Murata M; Hayashi T; Shimizu M; Mukae H; Toyoda K; Hotta T; Uchiumi T; Hayashi J
    Antiviral Res; 2016 Feb; 126():35-42. PubMed ID: 26692214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
    Vermehren J; Aghemo A; Falconer K; Susser S; Lunghi G; Zeuzem S; Colombo M; Weiland O; Sarrazin C
    J Hepatol; 2014 May; 60(5):913-9. PubMed ID: 24424305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
    Sarrazin C; Shiffman ML; Hadziyannis SJ; Lin A; Colucci G; Ishida H; Zeuzem S
    J Hepatol; 2010 Jun; 52(6):832-8. PubMed ID: 20385421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
    Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
    Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
    Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
    J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy.
    Ogawa E; Furusyo N; Murata M; Shimizu M; Toyoda K; Hotta T; Uchiumi T; Hayashi J
    Antivir Ther; 2017; 22(1):61-70. PubMed ID: 27632789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C.
    Ikezaki H; Furusyo N; Ihara T; Hayashi T; Ogawa E; Toyoda K; Taniai H; Kainuma M; Murata M; Hayashi J
    J Infect Chemother; 2011 Dec; 17(6):737-43. PubMed ID: 21528383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?
    Ikeda H; Okuse C; Watanabe T; Matsumoto N; Matsunaga K; Shigefuku R; Hattori N; Hiraishi T; Fukuda Y; Noguchi Y; Ishii T; Shima J; Nakahara K; Yamamoto H; Yasuda H; Yotsuyanagi H; Koike K; Itoh F; Suzuki M
    Turk J Gastroenterol; 2016 Mar; 27(2):165-72. PubMed ID: 27015621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
    Maasoumy B; Cobb B; Bremer B; Luk K; Halfon P; Aslam S; Manns MP; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2014 Jan; 39(1):85-92. PubMed ID: 24206524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
    Roomer R; van Vuuren AJ; Schutten M; Heijens A; Janssen HL; de Knegt RJ
    Antivir Ther; 2011; 16(5):771-4. PubMed ID: 21817199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
    Kanda T; Imazeki F; Yonemitsu Y; Mikami S; Takada N; Nishino T; Takashi M; Tsubota A; Kato K; Sugiura N; Tawada A; Wu S; Tanaka T; Nakamoto S; Mikata R; Tada M; Chiba T; Kurihara T; Arai M; Fujiwara K; Kanai F; Yokosuka O
    J Viral Hepat; 2011 Jul; 18(7):e292-7. PubMed ID: 21129130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Cento V; Di Paolo D; Di Carlo D; Micheli V; Tontodonati M; De Leonardis F; Aragri M; Antonucci FP; Di Maio VC; Mancon A; Lenci I; Manunta A; Taliani G; Di Biagio A; Nicolini LA; Nosotti L; Sarrecchia C; Siciliano M; Landonio S; Pellicelli A; Gasbarrini A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F
    Dig Liver Dis; 2015 Feb; 47(2):157-63. PubMed ID: 25544656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.